多西紫杉醇腹腔灌注化疗治疗晚期胃癌Ⅱ期临床研究  

Phase Ⅱ trial of Intraperitoneal chemotherapy with docetaxel inthe treatment of advanced gastric cancer

作　　者：黄万中[1] 蒋华[1] 刘燕文[1] 姜维美[1] 胡春霞[1] 张利[1] 贾建英[1] 

机构地区：[1]连云港市第二人民医院,江苏连云港222002

出　　处：《现代肿瘤医学》2011年第5期960-963,共4页Journal of Modern Oncology

基　　金：江苏省卫生厅面上基金资助项目(编号:H200771)

摘　　要：目的:探讨多西紫杉醇(DOC)腹腔灌注化疗(intraperitoneal chemotherapy,IPC)联合亚叶酸钙(CF)/5-氟尿嘧啶(5-FU)/奥沙利铂(OXA)静脉用药治疗晚期胃癌的临床疗效和安全性。方法:2007年7月至2009年9月,给与43例TNMⅢb-Ⅳ期胃癌患者(Ⅲb期19例,Ⅳ24期例)DOC 40mg/m2腹腔灌注d1,8,CF200mg/m2静脉滴注d1-5,5-FU 375mg/m2静脉滴注d1-5,OXA 135mg/m2静脉滴注d1方案,每21天为一周期,共2-4个周期,每2周期评价疗效。结果:总有效率(CR+PR)为58.1%(25/43),其中CR6.9%(3/43)、PR51.2%(22/43)。中位疾病进展时间(mTTP)为7.5(2.3-14.2)个月。一年生存率为67.4%。常见不良反应为腹痛、腹泻、骨髓抑制、胃肠道反应、脱发、口腔黏膜炎和外周神经毒性等。结论:DOC 40mg/m2腹腔灌注d1,8,联合CF/5-FU/OXA方案静脉用药治疗晚期胃癌疗效肯定,且不良反应可以耐受。Objective：To investigate the efficacy and safety of intraperitoneal chemotherapy with docetaxel combined with iv.leucovorin /fuorouracil/oxaliplatin in the treatment of advanced gastric cancer.Methods： All 43 patients with advanced gastric cancer were administered abdominal inwelling catheter conventionally.And then received docetaxel 40mg/m^2 ip.on day 1,8;leucovorin 200mg/m^2 iv.on day 1-5;fuorouracil 375 mg/m^2 iv.on day 1-5;oxaliplatin 135mg/m^2 iv.on day 1,three weeks as a cycle,each case received a total of 2-4 cycles.Results： Overall response rate（CR＋PR） was 58.1%（25/43）.mTTP was 7.5（2.3-14.2） months.One-year overall survival rate was 67.4%.The common side effects of intraperitoneal chemotherapy with docetaxel was abdominal pain,diarrhea,bone marrow suppression,stomatitis,alopecia,nausea,vomiting,and so on.Conclusion： Intraperitoneal chemotherapy with docetaxel（40mg/m^2 d1,8 ip） in the treatment of advanced gastric cancer is effective and tolerable.

关 键 词：胃癌 多西紫杉醇 腹腔灌注化疗 

分 类 号：R735.2[医药卫生—肿瘤]